Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).

Moccia, Alden Alberto; Schär, Sämi; Hayoz, Stefanie; Pirosa, Maria Cristina; Taverna, Christian; Novak, Urban; Kimby, Eva; Ghielmini, Michele; Zucca, Emanuele (2021). Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). British journal of haematology, 192(6), pp. 1031-1034. Wiley-Blackwell 10.1111/bjh.17045

Text bjh.17045.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (152kB) | Request a copy

The relapse of follicular lymphoma (FL) within 24 months (POD24) of chemoimmunotherapy has been associated with poor survival. We analyzed a pooled dataset of three randomized trials including FL patients with advanced disease, conducted by the Swiss Group for Clinical Cancer Research (SAKK). Overall, POD24 was observed in 27% of 318 patients, but rate variance among studies suggested that the rituximab schedule might affect POD24 rate. POD24 was associated with lower 10-year overall survival rates than in the reference group (69% vs. 77%; hazard ratio, 3·12; 95% confidence interval, 1·73-5·65). POD24 retains its prognostic validity in patients treated without chemotherapy and may represent a useful end-point for future studies.

Interest & Impact

Downloads

1 since deposited on 23 Sep 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item